[Predictive value of neutrophil to lymphocyte ratio on long-term outcomes of acute myocardial infarction patients with multivessel disease]
- PMID: 30669809
- DOI: 10.3760/cma.j.issn.0253-3758.2019.01.005
[Predictive value of neutrophil to lymphocyte ratio on long-term outcomes of acute myocardial infarction patients with multivessel disease]
Abstract
Objective: Patients with acute coronary syndrome due to multivessel disease (MVD) were at the highest risk of adverse cardiovascular events. Neutrophil to lymphocyte ratio (NLR) was proposed as a marker of cardiovascular risk. Present study evaluated the independent predictive value of NLR for acute myocardial infarction (AMI) patients with MVD. Methods: AMI patients with MVD (n=1 433) underwent percutaneous coronary intervention (PCI) between January 2013 and December 2013 were followed up for 2 years. Patients were divided into 2 sub-groups based on an optimal cut off value of NLR to predict 2-year all-cause mortality. The primary endpoint was all-cause death. The secondary endpoint was long-term major adverse cardiovascular and cerebrovascular events (MACCE). Results: By receiver operating characteristics curve analysis, the optimal cut-off value of admission NLR to predict 2-year all-cause mortality was 3.39 (area under the curve 0.765, sensitivity 71%, specificity 73%). The high NLR group(n=396) had higher prevalence of prior myocardial infarction, prior PCI and intra-aortic balloon pump use (IABP)(P<0.01). Compared to the low NLR group (n=1 037), patients in the high NLR group were older, had higher level of neutrophil count and high-sensitivity C-reactive protein (hs-CRP) (P<0.001), but lower level of lymphocyte count, estimated glomerular filtration rate (eGFR) and ejection fraction (P<0.001). During the follow-up period, rate of long-term all-cause death was significantly higher in the high NLR group than in the low NLR group (5.1% (20/396) vs. 0.8% (8/1 037), P<0.001). Cardiac death (4.0% (16/396) vs. 0.7% (7/1 037), P<0.001) and MACCE (21.7% (86/396) vs. 12.6% (131/1 037), P<0.001) were also significantly higher in the high NLR group than in the low NLR group. Multivariate Cox analysis showed that NLR ≥ 3.39 was determined as an independent predictor of 2-year all-cause mortality (HR=3.23, 95%CI 1.38-7.54, P=0.007) and MACCE (HR=1.58, 95%CI 1.19-2.10, P=0.002) in this patient cohort after adjusting for other risk factors. Correlation analysis showed that the NLR was positively correlated with hs-CRP levels (r=0.241, P<0.001). Conclusion: Our study demonstrates that admission NLR ≥ 3.39 is an independent predictor of long term all cause death and MACCE in AMI patients with MVD post PCI.
目的: 探讨中性粒细胞与淋巴细胞比值(NLR)对于急性心肌梗死(AMI)合并多支血管病变(MVD)患者远期预后的预测价值。方法: 该研究为前瞻性观察研究,连续纳入2013年1至12月于阜外医院行经皮冠状动脉介入治疗(PCI)的AMI合并MVD的患者1 433例。根据受试者工作特征(ROC)曲线确定NLR预测2年全因死亡的最佳临界值,分为高NLR组和低NLR组。主要临床终点为2年全因死亡,次要终点是2年主要不良心脑血管事件(MACCE)的复合终点。结果: ROC曲线结果显示NLR预测2年全因死亡临界值是3.39(曲线下面积是0.765,敏感度71%,特异度73%)。纳入的1 433例患者中,396例(27.6%)NLR≥3.39,归为高NLR组,1 037例NLR<3.39,归为低NLR组。高NLR组患者中既往心肌梗死、PCI、主动脉内球囊反搏(IABP)发生的比例均明显高于低NLR组(P均<0.01)。与低NLR组相比,高NLR组患者年龄较大、中性粒细胞计数较多、高敏C反应蛋白(hs-CRP)水平较高(P均<0.001),而淋巴细胞计数较少、左心室射血分数较低、估测的肾小球滤过率较低(P均<0.001)。2年随访结果显示,高NLR组患者2年全因死亡率[5.1%(20/396)比0.8%(8/1 037),P<0.001],MACCE发生率[21.7%(86/396)比12.6%(131/1 037),P<0.001)],心原性死亡率[4.0%(16/396)比0.7%(7/1 037),P<0.001]均明显高于低NLR组,支架内血栓和血运重建发生率均高于低NLR组(P均<0.05),两组患者心肌梗死、卒中和出血发生率差异均无统计学意义(P均>0.05)。Cox多因素回归分析结果显示,NLR≥3.39是AMI合并MVD患者全因死亡(HR=3.23,95%CI 1.38~7.54,P=0.007)和MACCE(HR=1.58,95%CI 1.19~2.10,P=0.002)的独立预测因子。NLR与hs-CRP相关性分析显示二者水平呈显著正相关(r=0.241,P<0.001)。结论: NLR是AMI合并MVD患者远期全因死亡和MACCE的独立预测因子,具有很强的预测价值。.
Keywords: Myocardial infarction; Neutrophil to lymphocyte ratio; Prognosis.
Similar articles
-
Predictive value of neutrophil to lymphocyte ratio in long-term outcomes of left main and/or three-vessel disease in patients with acute myocardial infarction.Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):551-557. doi: 10.1002/ccd.27495. Epub 2018 Jan 13. Catheter Cardiovasc Interv. 2018. PMID: 29330938
-
Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent.PLoS One. 2015 Jul 24;10(7):e0133934. doi: 10.1371/journal.pone.0133934. eCollection 2015. PLoS One. 2015. PMID: 26207383 Free PMC article.
-
Combined Use of Neutrophil to Lymphocyte Ratio and C-Reactive Protein Level to Predict Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.Korean Circ J. 2017 May;47(3):383-391. doi: 10.4070/kcj.2016.0327. Epub 2017 May 25. Korean Circ J. 2017. PMID: 28567089 Free PMC article.
-
Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis.Am J Emerg Med. 2021 Apr;42:60-69. doi: 10.1016/j.ajem.2021.01.006. Epub 2021 Jan 9. Am J Emerg Med. 2021. PMID: 33453617 Free PMC article.
-
Predictive role of neutrophil-to-lymphocyte ratio in metabolic syndrome: Meta-analysis of 70,937 individuals.BMC Endocr Disord. 2024 Aug 20;24(1):155. doi: 10.1186/s12902-024-01689-z. BMC Endocr Disord. 2024. PMID: 39164679 Free PMC article.
Cited by
-
The value of neutrophil-to-lymphocyte ratio in predicting severity of coronary involvement and long-term outcome of percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis.Egypt Heart J. 2024 Mar 28;76(1):39. doi: 10.1186/s43044-024-00469-3. Egypt Heart J. 2024. PMID: 38546902 Free PMC article. Review.
-
Diagnostic value of the creatine kinase-MB/creatine kinase and neutrophil/lymphocyte ratios in acute myocardial infarction.J Cardiothorac Surg. 2024 Apr 16;19(1):227. doi: 10.1186/s13019-024-02740-9. J Cardiothorac Surg. 2024. PMID: 38627839 Free PMC article.
-
Neutrophil-Lymphocyte Ratio as an Initial Screening Biomarker for Differential Diagnosis of Cushing's Syndrome from Nonfunctional Adenoma in Patients with an Adrenal Mass.Biomed Res Int. 2021 Feb 15;2021:6635594. doi: 10.1155/2021/6635594. eCollection 2021. Biomed Res Int. 2021. PMID: 33628798 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous